Unveiling Immediate Pseudo-Progression with Epcoritamab in Lymphoma Treatment: Case Series Exploration

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype in the United States, with around 40% of patients experiencing relapse or resistance to initial chemoimmunotherapy. Despite attempts to improve outcomes with treatments like autologous hematopoietic stem cell transplant (AHCT) or CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy, fewer than half achieve lasting remission. The recent FDA approval of CD20/CD3 BiTE therapies, such as Epcoritamab, has brought hope to heavily pretreated DLBCL cases.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 203 Source Type: research